SML0335
Remacemide hydrochloride
≥98% (HPLC)
别名:
2-Amino-N-(1-methyl-1,2-diphenylethyl)-acetamide hydrochloride, FPL 12924AA, PR 934-423A
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C17H20N2O · HCl
化学文摘社编号:
分子量:
304.81
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Quality Level
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
H2O: >10 mg/mL
storage temp.
room temp
SMILES string
Cl.CC(Cc1ccccc1)(NC(=O)CN)c2ccccc2
InChI
1S/C17H20N2O.ClH/c1-17(19-16(20)13-18,15-10-6-3-7-11-15)12-14-8-4-2-5-9-14;/h2-11H,12-13,18H2,1H3,(H,19,20);1H
InChI key
HYQMIUSWZXGTCC-UHFFFAOYSA-N
Biochem/physiol Actions
Remacemide possesses neuroprotective and anti-epileptic actions. It supports reducing the frequency of seizures. Remacemide is also known to be a potential therapeutic for Huntington′s disease.
Remacemide HCl is a low affinity NMDA antagonist with anticonvulsant properties.
Remacemide HCl is a low affinity NMDA antagonist with anticonvulsant properties. Remacemide also been shown to block voltage-dependent sodium channels.
Features and Benefits
This compound is featured on the Glutamate Receptors (Ion Channel Family) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Acute 1 - Eye Dam. 1
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Gabriele Schilling et al.
Experimental neurology, 187(1), 137-149 (2004-04-15)
The HD-N171-82Q (line 81) mouse model of Huntington's disease (HD), expresses an N-terminal fragment of mutant huntingtin (htt), loses motor function, displays HD-related pathological features, and dies prematurely. In the present study, we compare the efficacy with which environmental, pharmacological
D Chadwick et al.
Seizure, 9(8), 544-550 (2001-02-13)
Forty patients (33 male, 7 female) with refractory epilepsy were randomized to receive ascending weekly doses of adjunctive remacemide hydrochloride in a b.i.d. or q.i.d. regimen, or placebo for up to 1 month. Assessments included routine physical examination and laboratory
Robert Małek et al.
Polish journal of pharmacology, 55(5), 691-698 (2004-01-06)
Epilepsy belongs to common diseases of the brain. It affects approximately 1% of the population. The aim of epilepsy therapy is to keep the patient free of seizures without interfering with normal brain function. Unfortunately, about 30% of all epilepsies
Astrid Nehlig et al.
Epilepsy research, 52(3), 253-261 (2003-01-22)
The antiepileptic effects of remacemide were assessed in two models of genetically determined generalized epilepsy. The model of non-convulsive epilepsy used was a model of absence seizures, the GAERS (genetic absence epilepsy rats from Strasbourg), and the model of convulsive
K A Wesnes et al.
Epilepsy & behavior : E&B, 14(3), 522-528 (2008-12-30)
An international trial comparing remacemide hydrochloride with carbamazepine was undertaken in individuals with newly diagnosed epilepsy using a novel double-blind, parallel-group, double triangular sequential design. Patients with two or more partial or generalized tonic-clonic seizures in the previous year were
商品
We offers many products related to ion channel family glutamate receptors for your research needs.
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML0335-10MG | 04061832075587 |
| SML0335-50MG | 04061832260983 |
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持